Enzo Biochem, Inc.
ENZB
$0.5299
-$0.01-1.85%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.19% | -14.25% | -20.41% | -16.00% | 7.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.19% | -14.25% | -20.41% | -16.00% | 7.17% |
| Cost of Revenue | -8.65% | -18.02% | -9.61% | -25.94% | -4.18% |
| Gross Profit | -33.46% | -10.39% | -34.01% | 2.38% | 24.06% |
| SG&A Expenses | 3.83% | -15.80% | -33.93% | -42.38% | -50.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.72% | -16.78% | -25.95% | -36.98% | -36.45% |
| Operating Income | -65.88% | 26.68% | 33.86% | 63.04% | 75.54% |
| Income Before Tax | -11.40% | -44.61% | 45.89% | 87.07% | 73.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.40% | -44.61% | 45.89% | 87.07% | 73.02% |
| Earnings from Discontinued Operations | 53.21% | 86.94% | 67.59% | -118.45% | 87.81% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.62% | 49.85% | 48.97% | -123.30% | 80.11% |
| EBIT | -65.88% | 26.68% | 33.86% | 63.04% | 75.54% |
| EBITDA | -80.01% | 33.06% | 36.55% | 65.68% | 77.86% |
| EPS Basic | 9.83% | 51.49% | 50.99% | -122.32% | 80.81% |
| Normalized Basic EPS | -8.85% | -39.25% | 48.09% | 87.95% | 73.97% |
| EPS Diluted | 9.83% | 51.49% | 46.89% | -122.34% | 80.81% |
| Normalized Diluted EPS | -8.85% | -39.25% | 48.09% | 87.95% | 73.97% |
| Average Basic Shares Outstanding | 2.32% | 3.58% | 4.10% | 3.54% | 3.71% |
| Average Diluted Shares Outstanding | 2.32% | 3.58% | 4.10% | 3.54% | 3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |